Compare Aehr Test Systems (AEHR) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs Becton Dickinson and Co — how do they compare? Aehr Test Systems trades at $66.81 (market cap $2.11B), while Becton Dickinson and Co trades at $151.68 (market cap $43.07B). The key difference: Becton Dickinson and Co is far larger — about 20.4× Aehr Test Systems's market cap, and Becton Dickinson and Co pays a 2.69% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | BDX | |
|---|---|---|
Market Cap | $2.11B | $43.07B |
Sector | Technology | Health |
52-Week High | $116.58 | $185.39 |
52-Week Low | $13.29 | $135.49 |
Enterprise Value | $2.08B | $59.53B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
